Monitoring treatment in advanced lung cancer using liquid biopsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of liquid biopsy to monitor treatment in patients with advanced non-small cell lung cancer (NSCLC) receiving immunotherapy. It aims to optimize treatment monitoring by reducing ineffective treatments and minimizing unnecessary toxicity. The study will compare the clinical utility of circulating tumor DNA (ctDNA) measurements against traditional radiologic scans, which can be imprecise and challenging to interpret, especially after immunotherapy. By employing a randomized interventional multicenter approach, the study seeks to establish the cost-effectiveness and utility of liquid biopsy in everyday clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnosed, histologically verified, Non-Small Cell Lung Cancer (NSCLC)
* Advanced or locally advanced disease without curative intended treatment options
* Age \> 18 years
* Eastern Cooperative Oncology Group (ECOG) score of Performance Status (PS) 0-1
* Measurable disease according to the iRECIST criteria version 1.1.
* Eligible to first line immunotherapy (monotherapy)
* Signed informed consent

Exclusion Criteria:

* Targetable alterations in EGFR, ALK or ROS-1
* Other active cancers

Where it's running

• Department of Clinical Oncology
  Hillerød, Region H, Denmark Recruiting
• Department of Clinical Oncology and Palliative Care
  Næstved, Region Sjælland, Denmark Recruiting
• Department of Clinical Oncology and Palliative Care
  Roskilde, Region Sjælland, Denmark Recruiting
• Department of Oncology
  Aalborg, Denmark Not yet recruiting
• Department of Oncology
  Vejle, Denmark Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Amivantamab with platinum chemotherapy for metastatic EGFR‑mutant non‑small cell lung cancer

  This study will try giving amivantamab together with platinum chemotherapy to adults with metastatic NSCLC who have specific EGFR mutations to see how long their cancer stays controlled and how safe the treatment is.

  Recruiting at 11 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 15 other locations · NCT07563205

• OM-RCA-01 (anti-FGFR1 antibody) for metastatic tumors that express FGFR1

  This trial will try OM-RCA-01, an IV antibody given every two weeks, in adults with metastatic cancers whose tumors test positive for FGFR1 and who have progressed after standard treatments.

  Recruiting at 4 sites Phase 1/2 Kidney Cancer Research Bureau · Kazan' and 4 other locations · NCT07292168

• Proteomic-guided, risk-adapted therapy for advanced non-small cell lung cancer

  This trial tests whether using a proteomic test plus a toxicity risk tool to pick immune checkpoint inhibitor–based treatment can improve 12-month progression-free survival for people with previously untreated advanced non-small cell lung cancer.

  Recruiting at 4 sites Phase 2 University of California, Davis · Chico, California and 3 other locations · NCT07250477

• First-line nivolumab plus ipilimumab with short-course chemotherapy for metastatic non-small cell lung cancer

  This project will collect real-world data to see if nivolumab plus ipilimumab combined with a short course of platinum chemotherapy works well as first-line treatment for adults with metastatic non-small cell lung cancer who do not have EGFR or ALK alterations.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Lombardy · NCT07190677

• PF-08046054 (SGN-PDL1V) versus docetaxel for PD-L1–positive advanced non-small cell lung cancer

  This test compares PF-08046054 (SGN-PDL1V) with docetaxel for adults whose PD-L1–positive advanced NSCLC progressed after PD-1/PD-L1 inhibitors, platinum chemotherapy, and targeted treatments when appropriate.

  Recruiting at 454 sites Phase 3 Pfizer · Alabaster, Alabama and 468 other locations · NCT07144280

• Cemiplimab guided by ctDNA levels (PALACE)

  This study will see if starting adults with advanced (stage IIIB/C or IV) non-small cell lung cancer and PD-L1 ≥50% on cemiplimab, then using ctDNA and early scans to decide whether to add chemotherapy, can improve overall survival.

  Recruiting at 19 sites Phase 2 Fundación GECP · Alicante, Alicante and 19 other locations · NCT06917573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.